Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that both single- and double-spin PRP preparation methods significantly increased thrombocyte counts and improved hair parameters in males with androgenetic alopecia, with the single-spin method showing a more significant increase in thrombocyte count.

In this study, platelet-rich plasma injections improved hair density by 19.17% in men with androgenetic alopecia over six months, although results varied by alopecia pattern.

In this study, preoperative use of finasteride was associated with reduced blood loss and vascular endothelial growth factor expression during TURP, suggesting a potential benefit in preventing transurethral resection syndrome.

Systematic end-of-trial biopsies are the most reliable way to assess outcomes.

New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.

This study found that platelet-rich plasma, used as a sole treatment in male patients with androgenetic alopecia, may improve hair growth over a three-month period.

In a testosterone-induced mouse model, this study found that exosomes from injectable Platelet-Rich Fibrin (i-PRF) significantly reduced inflammation, oxidative stress, and apoptosis, while enhancing hair regeneration, with the greatest improvements seen when combined with minoxidil, suggesting potential as a novel treatment for androgenetic alopecia.

This study reported that a newly formulated Curcumin-loaded proniosome, named F5, exhibited enhanced antiviral efficacy, stability, and safety when compared to Curcumin alone, and improved the therapeutic performance of Acyclovir by reducing its effective dose against Herpes simplex virus.

This abstract does not present new clinical findings or a research study.

This Phase II study found that BAY 43-9006, given at 400 mg orally twice daily, led to stable disease in 30% and tumor reduction in 40% of renal cell carcinoma patients.

This article discusses the factors driving the platelet-rich plasma market in dermatology and reports no clinical results; it highlights the need for more affordable and accessible treatments.

In this study, tebentafusp-tebn improved overall survival in patients with metastatic uveal melanoma compared to standard therapies, despite higher rates of significant adverse events.

In this study, a newly designed protein degrader targeting androgen receptors showed promise in reversing hair regrowth inhibition in a mouse model of androgenetic alopecia, suggesting potential as a novel and safe treatment strategy.

This study found no significant immediate hair growth or loss reduction from PRP treatment compared to Finastride and placebo, but differences emerged after three to six months.

This study found that proxalutamide treatment significantly reduced 30-day hospitalization rates in women with mild-to-moderate COVID-19 compared to placebo, with no safety issues identified.

This study found that a three-month regimen of leucoselect phytosome, a grape seed extract complex, was well tolerated and significantly reduced bronchial proliferation markers in heavy active and former smokers.

This review discusses the use of platelet-rich plasma in urology and emphasizes the need for further multicenter studies to explore its potential benefits.

This study found that androgenetic alopecia patients treated with a combination of PRP and systemic therapy experienced greater but non-significant improvements in hair density and width compared to PRP monotherapy, without additional adverse effects, suggesting potential benefits for further exploration of combination regimens.

This study found that platelet-rich plasma treatments improved hair density and regrowth in men and women with androgenetic alopecia, with better results when combined with minoxidil compared to finasteride.

This review explores the potential links between PRP treatments for hair loss and scalp skin cancer risk, finding current evidence supports PRP's safety but emphasizes the need for further studies and routine monitoring.

The new topical product combined with finasteride significantly increased hair thickness without side effects.

PrEP doesn't increase STI risk in high-risk men, anti-androgen drugs may lower ICU admission for male COVID-19 patients, a 3-point injection is better for crow's feet, and the 'Geriatric-8' tool could help assess frailty in older skin cancer patients.

This article proposes a mechanistic model for how platelet-rich plasma therapy may stimulate hair growth in androgenetic alopecia by promoting vascularization and activating specific signaling pathways, but it reports no new experimental results.

This study found that some synthesized heterocyclic derivatives showed promising 5α-reductase inhibitor, antiviral, and anti-tumor activities, surpassing several reference drugs in effectiveness.

This study found that using intraoperative platelet-rich plasma in follicular unit extraction hair transplantation significantly improved graft survival, accelerated hair regrowth, and increased patient satisfaction compared to the procedure without PRP.

This study suggests that PF-0998425 is an effective androgen receptor antagonist for sebum control and androgenetic alopecia with rapid metabolism reducing the risk of systemic side effects.

This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.

This review discusses significant developments in prostate cancer risk assessment, diagnosis, and treatment, but reports no new clinical results; the authors emphasize the evolving importance of prognostic factors and treatment implications.

This article discusses the use of Platelet Rich Plasma therapy for skin rejuvenation and hair loss and reports no new clinical results, noting its minimally invasive nature and effect on skin texture and elasticity.